The FDA has designated 503A compounding pharmacies as those with outsourcing facilities that may manufacture large batches with or without prescriptions to be sold to healthcare facilities for office use only. These entities are a crucial part of the FDA attempting to limit the effect that drug shortages have on American healthcare.